Mark Zuckerberg's pushback on slowing AI development is seen as deliberately sidestepping the existential risk debate. He focuses on user-level alignment and presents standard product development delays as major safety concessions. Critics argue this is a disingenuous tactic that talks past the AI safety community's core concerns about catastrophic outcomes.

OpenAI CEO Sam Altman's suggestion of slowing AI development is likely a strategic move. It could be a trial balloon to appease doomsayers and gauge public opinion, rather than a genuine commitment to cede their market lead.

Top AI labs like Anthropic publicly state that slowing down AI development would benefit society. However, they are caught in a strategic trap: a unilateral pause is unviable. Without a global agreement, any lab that pauses simply allows less cautious competitors to seize the lead, potentially making the ecosystem less safe.

Framing an AI development pause as a binary on/off switch is unproductive. A better model is to see it as a redirection of AI labor along a spectrum. Instead of 100% of AI effort going to capability gains, a 'pause' means shifting that effort towards defensive activities like alignment, biodefense, and policy coordination, while potentially still making some capability progress.

Tech leaders state they would support an AI development pause if competitors, especially China, also agreed. This is a strategic PR move, as they know a global consensus is unachievable. It allows them to appear responsible about AI safety without any actual risk of having to slow down progress.

Skeptics argue the call to 'pace' AI development is primarily a business strategy. They claim labs need to reduce massive model training costs and explain slowing growth to become viable for an IPO, making the slowdown a matter of economic necessity disguised as a safety concern.

The focus on AI risk overlooks the opportunity cost of "pacing." Delaying frontier model development, while potentially safer, also pushes back the timeline for major societal benefits like AI-driven scientific discoveries and disease cures, creating a difficult societal trade-off.

Acknowledging their safety plans might be inadequate, leaders from multiple frontier labs have begun to seriously entertain a coordinated slowdown. This represents a major shift, as they also explore legal "safe harbors" to collaborate on safety without triggering antitrust violations, breaking the frame of the current race.

The default assumption is that slowing innovation is inherently bad. With a technology as potent as AI, a deliberate slowdown is a feature, providing critical time to understand the systems, manage disruptions, and build governance structures before irreversible consequences occur. A true halt is not the alternative.